HPV testing and Pap test market seen reaching $8.6B by 2030

The HPV testing and Pap test market is projected to grow from $4.83 billion in 2025 to $5.41 billion in 2026, with demand driven by cervical cancer screening, molecular diagnostics and preventive healthcare. The Business Research Company says North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - HPV testing and Pap tests are core cervical cancer screening tools that can detect precancerous changes early. - Faster screening adoption can improve early intervention and reduce cervical cancer risk. - The market's growth reflects broader demand for preventive diagnostics and automated laboratory systems.

What happened: - The Business Research Company released its HPV Testing And Pap Test Market Report 2026, covering market size, trends and a global forecast through 2035. - The report pegs the market at $4.83 billion in 2025 and $5.41 billion in 2026. - The report forecasts the market will reach $8.6 billion by 2030. - The company published a free sample of the report. - The company also posted the full market report.

The details: - The 2025-to-2026 growth rate is 12.0%. - The forecast period through 2030 implies a 12.3% CAGR. - Historical growth has been supported by expanded cervical cancer screening programs, greater awareness of women's health, higher Pap test use, growth in diagnostic laboratory networks and standardized screening procedures. - Future growth is expected to come from broader use of molecular diagnostic technologies, population-wide screening, automated laboratory systems and preventive healthcare investment. - Key trends include wider use of HPV DNA-based screening, liquid-based cytology, automated diagnostic platforms and expanded co-testing for cervical screening. - The report says improved early cancer detection accuracy is becoming a bigger focus.

Between the lines: - Cervical cancer prevalence is a major demand driver because insufficient screening can delay diagnosis and treatment. - Cancer Council Australia reported in May 2025 that 231 women in Victoria were diagnosed with invasive cervical cancer in 2023, equal to 6.4 cases per 100,000 women. - That diagnosis data underscores why screening market demand remains tied to disease burden. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The Business Research Company expects continued market expansion as molecular testing and automated systems become more common. - Wider co-testing and HPV DNA-based screening may shape how providers approach cervical cancer prevention. - The report highlights new 2026 features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - Screening demand, cancer prevention priorities and lab automation are pushing the HPV testing and Pap test market into sustained double-digit growth.